^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
Published date:
05/28/2021
Excerpt:
...GO was independently associated with improved EFS, improved DFS, and reduced RR....GO added to conventional chemotherapy improved outcomes for KMT2A-r AML; consolidation with HSCT may further enhance outcomes.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.20.03048
Trial ID:
